DYN
$17.56-0.24 (-1.35%)
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including progra...
Recent News
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.
Dyne Therapeutics Targets 2026 “Breakout Year” With DMD BLA Plans and DM1 Milestones at Stifel Conference
Dyne Therapeutics (NASDAQ:DYN) executives outlined a slate of 2026 operational and regulatory milestones during a discussion with Stifel, emphasizing plans to transition toward a commercial-stage organization while advancing multiple neuromuscular disease programs. Chief Financial Officer Erick Luc
Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data
Dyne Therapeutics (NasdaqGS:DYN) has initiated the Phase 3 Harmonia trial of DYNE-101 in myotonic dystrophy type 1, following alignment with the FDA on the study design. The Harmonia trial is a pivotal study focused on clinically meaningful endpoints tied to key functional impairments in myotonic dystrophy type 1. New long term data from the Phase 1/2 DELIVER trial of DYNE-251 in Duchenne muscular dystrophy report improvements in cardiac and lung function. These updates highlight clinical...
Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 11 Best Day Trading Stocks to Buy Now. Earlier this month, Dyne Therapeutics Inc. (NASDAQ:DYN) announced important updates for its DMD and DM1 programs. The firm revealed that it planned to submit an accelerated application for its DMD drug to target a launch in the first quarter […]
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 Stocks Investors Are Watching. Dyne Therapeutics saw its share prices jump by 11.81 percent on Tuesday to close at $19.78 apiece, after an investment firm reiterated a triple-digit upside potential for its stock. In a market report, Jefferies reiterated its “buy” issuance for Dyne Therapeutics Inc. […]